Does Anyone Recall ARNA's Panel? (ARNA, the $1.80 Stock That Soared to $13.50)
"FDA scientists’ concerns that the drug carried heart-valve risks — a problem that also plagued the weight-loss drug fenfluramine, which was taken off the market."
"After reviewing FDA briefing documents, Leerink notes that the FDA is asking the panel to answer only one question in deciding whether or not to recommend Arena's Lorcaserin : Do the benefits of lorcaserin outweigh the risks? The firm believes that the use of only one question is negative for lorcaserin, and Leeink also notes that the FDA's statistician is contending that the drug's efficacy hasn't been fully proven by a statistically significant level."
THOSE WERE SERIOUS ISSUES.
Reuters spun bogus issues regarding Probuphine today, thereby enabling Titan shares to be stolen from the moms and pops.